Clinical Study Results, Acquisitions, Joint Ventures and Awards for Contributions to the Technology Industry - Research Report on Medtronic, Edwards Lifesciences, Opko, LifePoint, and Allscripts

NEW YORK, September 11, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts' Corner announced new research reports highlighting Medtronic, Inc. (NYSE: MDT), Edwards Lifesciences Corp. (NYSE: EW), Opko Health, Inc. (NYSE: OPK), LifePoint Hospitals Inc. (NASDAQ: LPNT), and Allscripts Healthcare Solutions, Inc. (NASDAQ: MDRX). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Medtronic, Inc. Research Report

On September 3, 2013, Medtronic Inc. (Medtronic) announced the final three-year results from Symplicity HTN-1, the first and longest running clinical study investigating the safety and efficacy of renal denervation. According to the Company, 88 patients were available for the 36 month evaluation following the treatment with the Symplicity(TM) renal denervation system. Medtronic reported that the patients demonstrated sustained reductions in blood pressure year-over-year and approximately 50% of the patients achieved goal of a systolic blood pressure <140 mm Hg despite having a mean systolic blood pressure of 169.8 mm Hg pre-denervation. Professor Henry Krum, Principal Investigator of Symplicity HTN-1 and Chair of Medical Therapeutics, Professor of Medicine and Director of the Monash Centre of Cardiovascular Research and Education in Therapeutics, Melbourne, Australia said, "Achieving goal of below 140 mm Hg in about half of these patients is impressive considering that these patients had very high baseline blood pressures despite being on multiple pharmaceutical agents." The Full Research Report on Medtronic, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/bc94_MDT]

--

Edwards Lifesciences Corp. Research Report

On September 3, 2013, Edwards Lifesciences Corp. (Edwards Lifesciences) announced that a new post-hoc data analysis from the PARTNER Trial showed that diabetic patients with aortic stenosis in need of heart valve replacement, but at high surgical risk, experienced a 35% lower all-cause mortality one year after treatment with transcatheter aortic valve replacement (TAVR), as compared to those treated with surgical aortic valve replacement. In the analysis of diabetic patients in the as-treated high-risk cohort of The PARTNER Trial, the Company reported that one-year all-cause mortality was 18% for patients treated with the Edwards SAPIEN valve delivered via the femoral artery or a small incision between the ribs. Additionally, the analysis showed that diabetic patients treated with TAVR experienced quicker quality of life improvement and lower one-year rates of renal failure than those treated with surgery. The Full Research Report on Edwards Lifesciences Corp. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/48b8_EW]

--

Opko Health, Inc. Research Report

On August 29, 2013, OPKO Health Inc. (OPKO) announced the completion of its acquisition of PROLOR Biotech Inc. (PROLOR). Pursuant to the acquisition, PROLOR stockholders will receive 0.9951 shares of OPKO common stock for each share of PROLOR common stock. "We are pleased to complete the acquisition of PROLOR and broaden our portfolio of market-transforming therapies in selected specialty markets," commented Dr. Phillip Frost, OPKO's Chairman and CEO. "PROLOR's drug product candidates for growth hormone deficiency, hemophilia, obesity and diabetes, along with its broadly applicable technology platforms and efficient research and development center, are highly valuable assets that complement OPKO's growth strategy." The Full Research Report on Opko Health, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/cd43_OPK]

--

LifePoint Hospitals Inc. Research Report

On September 4, 2013, LifePoint Hospitals Inc. (LifePoint) announced that it has signed a definitive agreement with the Fauquier Health Board of Directors to form a joint venture to jointly own and operate Fauquier Health. Under the terms of the agreement, LifePoint will own 80% of the joint venture while Fauquier Health and the Warrenton community would retain 20% of the ownership stake. LifePoint Chairman and CEO William F. Carpenter III said, "We have enjoyed learning more about Fauquier Health and working with the Fauquier board and leadership team to reach this agreement for the proposed joint venture. We are excited about the opportunities for us to work together to enhance healthcare in this region." The Full Research Report on LifePoint Hospitals Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/f06d_LPNT]

--

Allscripts Healthcare Solutions, Inc. Research Report

On September 6, 2013, Allscripts Healthcare Solutions, Inc. (Allscripts) announced that Baylor Health Care System has been the recipient of the 2013 Tech Titans Technology Adopter Award for its successful design and implementation of innovations enabled by Allscripts Open Solutions platform. According to Allscripts, the award recognizes companies and individuals who have made outstanding contributions to the technology industry and to the technology industry in North Texas. The Company informed that several custom components for its Sunrise Clinical Manager were developed by Baylor to improve the adoption and use of Computerized Physician Order Entry (CPOE) and the use of electronic physician documentation. Paul M. Black, President and CEO of Allscripts congratulated Baylor for this special recognition. The Full Research Report on Allscripts Healthcare Solutions, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/1787_MDRX]

----

EDITOR NOTES:

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

http://www.analystscorner.com

SOURCE Analysts' Corner